Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | AZD5991 |
Synonyms | |
Therapy Description |
AZD5991 binds to and inhibits Mcl1, potentially resulting in increased tumor cell apoptosis and decreased tumor growth (Cancer Res July 1 2017 (77) (13 Supplement) DDT01-02, PMID: 32204955). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
AZD5991 | AZD-5991|AZD 5991 | MCL1 Inhibitor 18 | AZD5991 binds to and inhibits Mcl1, potentially resulting in increased tumor cell apoptosis and decreased tumor growth (Cancer Res July 1 2017 (77) (13 Supplement) DDT01-02, PMID: 32204955). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
PTEN loss | glioblastoma | sensitive | AZD5991 | Preclinical - Cell culture | Actionable | In a preclinical study, AZD5991 treatment inhibited proliferation of PTEN-deficient glioblastoma cells in culture (PMID: 32737157). | 32737157 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03218683 | Phase I | AZD5991 | Study of AZD5991 in Relapsed or Refractory Haematologic Malignancies. | Terminated | USA | 0 |